BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 17234409)

  • 1. Butyl 2-(4-[1.1'-biphenyl]-4-yl-1H-imidazol-2-yl)ethylcarbamate, a potent sodium channel blocker for the treatment of neuropathic pain.
    Liberatore AM; Schulz J; Favre-Guilmard C; Pommier J; Lannoy J; Pawlowski E; Barthelemy MA; Huchet M; Auguet M; Chabrier PE; Bigg D
    Bioorg Med Chem Lett; 2007 Mar; 17(6):1746-9. PubMed ID: 17234409
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 3-(4-phenoxyphenyl)pyrazoles: a novel class of sodium channel blockers.
    Yang J; Gharagozloo P; Yao J; Ilyin VI; Carter RB; Nguyen P; Robledo S; Woodward RM; Hogenkamp DJ
    J Med Chem; 2004 Mar; 47(6):1547-52. PubMed ID: 14998340
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 2-Alkyl-4-arylimidazoles: structurally novel sodium channel modulators.
    Liberatore AM; Schulz J; Pommier J; Barthelemy MA; Huchet M; Chabrier PE; Bigg D
    Bioorg Med Chem Lett; 2004 Jul; 14(13):3521-3. PubMed ID: 15177465
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthesis and SAR of 1,2-trans-(1-hydroxy-3-phenylprop-1-yl)cyclopentane carboxamide derivatives, a new class of sodium channel blockers.
    Ok D; Li C; Abbadie C; Felix JP; Fisher MH; Garcia ML; Kaczorowski GJ; Lyons KA; Martin WJ; Priest BT; Smith MM; Williams BS; Wyvratt MJ; Parsons WH
    Bioorg Med Chem Lett; 2006 Mar; 16(5):1358-61. PubMed ID: 16337121
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Potent analgesic effects of a putative sodium channel blocker M58373 on formalin-induced and neuropathic pain in rats.
    Akada Y; Ogawa S; Amano K; Fukudome Y; Yamasaki F; Itoh M; Yamamoto I
    Eur J Pharmacol; 2006 May; 536(3):248-55. PubMed ID: 16603152
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 3-Oxoisoindoline-1-carboxamides: potent, state-dependent blockers of voltage-gated sodium channel Na(V)1.7 with efficacy in rat pain models.
    Macsari I; Besidski Y; Csjernyik G; Nilsson LI; Sandberg L; Yngve U; Ahlin K; Bueters T; Eriksson AB; Lund PE; Venyike E; Oerther S; Hygge Blakeman K; Luo L; Arvidsson PI
    J Med Chem; 2012 Aug; 55(15):6866-80. PubMed ID: 22770500
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery of a novel class of benzazepinone Na(v)1.7 blockers: potential treatments for neuropathic pain.
    Hoyt SB; London C; Gorin D; Wyvratt MJ; Fisher MH; Abbadie C; Felix JP; Garcia ML; Li X; Lyons KA; McGowan E; MacIntyre DE; Martin WJ; Priest BT; Ritter A; Smith MM; Warren VA; Williams BS; Kaczorowski GJ; Parsons WH
    Bioorg Med Chem Lett; 2007 Aug; 17(16):4630-4. PubMed ID: 17588748
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery of potent furan piperazine sodium channel blockers for treatment of neuropathic pain.
    Drizin I; Gregg RJ; Scanio MJ; Shi L; Gross MF; Atkinson RN; Thomas JB; Johnson MS; Carroll WA; Marron BE; Chapman ML; Liu D; Krambis MJ; Shieh CC; Zhang X; Hernandez G; Gauvin DM; Mikusa JP; Zhu CZ; Joshi S; Honore P; Marsh KC; Roeloffs R; Werness S; Krafte DS; Jarvis MF; Faltynek CR; Kort ME
    Bioorg Med Chem; 2008 Jun; 16(12):6379-86. PubMed ID: 18501613
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 2,4(5)-Diarylimidazoles: synthesis and biological evaluation of a new class of sodium channel blockers against hNa(v)1.2.
    Rivara M; Baheti AR; Fantini M; Cocconcelli G; Ghiron C; Kalmar CL; Singh N; Merrick EC; Patel MK; Zuliani V
    Bioorg Med Chem Lett; 2008 Oct; 18(20):5460-2. PubMed ID: 18818069
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 2,4(5)-diarylimidazoles as inhibitors of hNaV1.2 sodium channels: pharmacological evaluation and structure-property relationships.
    Fantini M; Rivara M; Zuliani V; Kalmar CL; Vacondio F; Silva C; Baheti AR; Singh N; Merrick EC; Katari RS; Cocconcelli G; Ghiron C; Patel MK
    Bioorg Med Chem; 2009 May; 17(10):3642-8. PubMed ID: 19394229
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel cyclopentane dicarboxamide sodium channel blockers as a potential treatment for chronic pain.
    Shao PP; Ok D; Fisher MH; Garcia ML; Kaczorowski GJ; Li C; Lyons KA; Martin WJ; Meinke PT; Priest BT; Smith MM; Wyvratt MJ; Ye F; Parsons WH
    Bioorg Med Chem Lett; 2005 Apr; 15(7):1901-7. PubMed ID: 15780630
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery of potent and use-dependent sodium channel blockers for treatment of chronic pain.
    Liang J; Brochu RM; Cohen CJ; Dick IE; Felix JP; Fisher MH; Garcia ML; Kaczorowski GJ; Lyons KA; Meinke PT; Priest BT; Schmalhofer WA; Smith MM; Tarpley JW; Williams BS; Martin WJ; Parsons WH
    Bioorg Med Chem Lett; 2005 Jun; 15(11):2943-7. PubMed ID: 15878274
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phenyl isoxazole voltage-gated sodium channel blockers: structure and activity relationship.
    Macsari I; Sandberg L; Besidski Y; Gravenfors Y; Ginman T; Bylund J; Bueters T; Eriksson AB; Lund PE; Venyike E; Arvidsson PI
    Bioorg Med Chem Lett; 2011 Jul; 21(13):3871-6. PubMed ID: 21641215
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 20(S)-protopanaxadiol and the ginsenoside Rh2 inhibit Na+ channel-activated depolarization and Na+ channel-dependent amino acid neurotransmitter release in synaptic fractions isolated from mammalian brain.
    Duan Y; Nicholson RA
    Comp Biochem Physiol C Toxicol Pharmacol; 2008 Apr; 147(3):351-6. PubMed ID: 18262850
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Subtype-selective Na(v)1.8 sodium channel blockers: identification of potent, orally active nicotinamide derivatives.
    Kort ME; Atkinson RN; Thomas JB; Drizin I; Johnson MS; Secrest MA; Gregg RJ; Scanio MJ; Shi L; Hakeem AH; Matulenko MA; Chapman ML; Krambis MJ; Liu D; Shieh CC; Zhang X; Simler G; Mikusa JP; Zhong C; Joshi S; Honore P; Roeloffs R; Werness S; Antonio B; Marsh KC; Faltynek CR; Krafte DS; Jarvis MF; Marron BE
    Bioorg Med Chem Lett; 2010 Nov; 20(22):6812-5. PubMed ID: 20855211
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery of isoxazole voltage gated sodium channel blockers for treatment of chronic pain.
    Shao PP; Ye F; Weber AE; Li X; Lyons KA; Parsons WH; Garcia ML; Priest BT; Smith MM; Felix JP; Williams BS; Kaczorowski GJ; McGowan E; Abbadie C; Martin WJ; McMasters DR; Gao YD
    Bioorg Med Chem Lett; 2009 Sep; 19(18):5334-8. PubMed ID: 19683443
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Substituted biaryl oxazoles, imidazoles, and thiazoles as sodium channel blockers.
    Tyagarajan S; Chakravarty PK; Zhou B; Fisher MH; Wyvratt MJ; Lyons K; Klatt T; Li X; Kumar S; Williams B; Felix J; Priest BT; Brochu RM; Warren V; Smith M; Garcia M; Kaczorowski GJ; Martin WJ; Abbadie C; McGowan E; Jochnowitz N; Parsons WH
    Bioorg Med Chem Lett; 2010 Sep; 20(18):5536-40. PubMed ID: 20709552
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Imidazopyridines: a novel class of hNav1.7 channel blockers.
    London C; Hoyt SB; Parsons WH; Williams BS; Warren VA; Tschirret-Guth R; Smith MM; Priest BT; McGowan E; Martin WJ; Lyons KA; Li X; Karanam BV; Jochnowitz N; Garcia ML; Felix JP; Dean B; Abbadie C; Kaczorowski GJ; Duffy JL
    Bioorg Med Chem Lett; 2008 Mar; 18(5):1696-701. PubMed ID: 18243692
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The design, preparation and SAR of novel small molecule sodium (Na(+)) channel blockers.
    Ashwell MA; Lapierre JM; Kaplan A; Li J; Marr C; Yuan J
    Bioorg Med Chem Lett; 2004 May; 14(9):2025-30. PubMed ID: 15080972
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ralfinamide. Newron Pharmaceuticals.
    Cattabeni F
    IDrugs; 2004 Oct; 7(10):935-9. PubMed ID: 15478019
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.